Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
Recruiting
Observational Study
Immune-Related Adverse Events
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study aims to comprehensively characterize immune-related adverse events (irAEs) occurring during immune checkpoint inhibitor (ICI) therapy in cancer patients and to evaluate the safety and clinical outcomes of ICI rechallenge following irAE resolution.
In addition to detailed clinical data collection, the study incorporates biospecimen acquisition, when clinically indicated an…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years old) with a diagnosis of malignant tumor.
* Received treatment with immune checkpoint inhibitors (including anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 agents).
* Developed documented immune-related adverse events (irAEs) during ICI therapy, as determined by tr…
Contacts